XML 34 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - AstraZeneca Agreements [Member] - USD ($)
$ in Millions
3 Months Ended 9 Months Ended 27 Months Ended
Jul. 30, 2013
Jun. 30, 2015
Sep. 30, 2015
Mar. 31, 2014
Sep. 30, 2015
U.S./RoW [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expected upfront, non-contingent and time-based payments $ 374.0        
Upfront payments received         $ 312.0
Development and regulatory approval milestones 550.0        
Commercial sales milestone 325.0        
Shared development costs 233.0        
Additional consideration based on net sales description     Low 20% range    
Contingent payment 62.0        
U.S./RoW [Member] | Development Milestones [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Receipt of development milestone payment   $ 15.0      
China [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Upfront payments received       $ 12.0  
Development and regulatory approval milestones 161.0        
Commercial sales milestone 167.5        
Proceeds from upfront payments 28.2        
Contingent payment $ 20.0